Incyte (INCY) Q1 Earnings and Revenues Top Estimates

分组1 - Incyte reported quarterly earnings of $1.16 per share, exceeding the Zacks Consensus Estimate of $1.01 per share, and showing an increase from $0.64 per share a year ago, resulting in an earnings surprise of 14.85% [1] - The company achieved revenues of $1.05 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.66%, and up from $880.89 million year-over-year [2] - Incyte has surpassed consensus revenue estimates four times over the last four quarters, indicating a positive trend in revenue performance [2] 分组2 - The stock has underperformed, losing about 13.8% since the beginning of the year, compared to a decline of 6% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $1.42 on revenues of $1.14 billion, and for the current fiscal year, it is $5.81 on revenues of $4.68 billion [7] - The Medical - Biomedical and Genetics industry, to which Incyte belongs, is currently ranked in the top 31% of Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]